Let’s explore “Dupilumab: understanding the IL-4 and IL-13 target”

Dupilumab, sold as Dupixent, is a prescribed antibody medicine that acts on IL-4 receptor alpha.

IL13 encodes interleukin-13, a cytokine involved in Th2 immune responses, mucus-related processes and tissue remodeling. It overlaps with some IL-4 functions but is not the same signal.

IL4 encodes interleukin-4, a cytokine involved in Th2 immune responses and antibody class switching, including pathways related to IgE. It operates alongside IL-5 and IL-13 rather than representing all allergic biology by itself.

How the Purser approach moves from a nutrient finding to priorities, a manageable plan and reassessment.

Kids with cystic fibrosis often have high levels of inflammatory cytokines like IL-4, IL-5, IL-8, and IL-13, which damage the lungs. Research shows raising glutathione can lower these cytokines, yet most products don’t work. VARS Glutathion

Kids with cystic fibrosis often have high levels of inflammatory cytokines like IL-4, IL-5, IL-8, and IL-13, which damage the lungs. Research shows raising glutathione can lower these cytokines, yet most products don’t work. VARS Glutathion

… explains the shared IL-4 receptor alpha signaling pathway. Dupilumab is discussed as a medicine targeting this pathway; suitability depends on the diagnosed condition. Bring these questions to your visit Ask which result is being discusse…

Infliximab, sold as Remicade and as biosimilars, is a prescribed antibody medicine that targets TNF-alpha.

…4/IL-13 signaling, eosinophils, and the IL-4 receptor alpha target of dupilumab. He considers oxidative stress alongside approaches such as dietary evaluation and prescribed treatment. Bring these questions to your visit Ask which findings…

Explore interleukin-4, Th2 cells, immunoglobulin E (IgE), and allergic and atopic conditions.

PURSER WELLNESSThe Hidden Molecule Driving Inflammation: Understanding the Purser Model of HomocysteineFrom the reading room

Most people have never heard of homocysteine , yet this small molecule may hold the key to understanding inflammation, cardiovascular disease, neurological problems, and many chronic conditions. For decades, homocysteine was viewed as a toxic substance in the blood. Doctors were taught that lowering it with B-vitamins might reduce heart disease risk. But research results were inconsistent, leaving many physicians unsure whether homocysteine truly mattered. New research and clinical observations are changing that view. We introduce a new framework called the Purser Model , which explains why ho

CMA and antioxidant or redox results describe different aspects of cellular nutrient function.